<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03362697</url>
  </required_header>
  <id_info>
    <org_study_id>CSUB 0139</org_study_id>
    <nct_id>NCT03362697</nct_id>
  </id_info>
  <brief_title>Lactobacillus Reuteri for Treatment of Uncomplicated UTI in Pregnant Women</brief_title>
  <acronym>UTIPregnant</acronym>
  <official_title>Randomized Clinical Trial on the Safety and Efficacy of Lactobacillus Reuteri DSM 16666/ATCC 55845 &amp; Lactobacillus Reuteri DSM 17938 for Treatment of Pregnant Women With Asymptomatic Bacteriuria or Uncomplicated Acute Cystitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovacion y Desarrollo de Estrategias en Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioGaia AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Innovacion y Desarrollo de Estrategias en Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prevalence of uro-genital infections during pregnancy move between 7% to 12% in developed
      countries, meanwhile in developing countries this figure moved between 14% and until 55%,
      such is the case of Mexico. Meanwhile use of antibiotics for 3 to 7 days had established as a
      standard of care, the use of non-antibiotic therapy, such as cranberry powder or probiotics
      for prevention/treatment of this conditions is scarce. Randomized controlled trial aimed to
      evaluate the safety and efficacy of probiotic vs. antibiotics to treat pregnant women with
      uncomplicated cystitis or asymptomatic bacteriuria
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized controlled trial, aimed to evaluate the efficacy of Lactobacillus reuteri DSM
      16666/ATCC 55845 &amp; Lactobacillus reuteri DSM 17938 for the treatment of pregnant women with
      asymptomatic bacteriuria or uncomplicated acute cystitis. As primary outcome we will evaluate
      the number of cases with clinical (symptoms severity) or bacteriological cure in pregnant
      women with uncomplicated cystitis or asymptomatic bacteriuria after 7 days treatment with
      probiotics vs. placebo. As secondary outcome we will evaluate a) rate of recurrence cases in
      each group; b) time to relapse; c) frequency of pyelonephritis; d) birth weight and head
      circumference; d) number of cases of preterm babies (less than 36 weeks of gestation); e)
      frequency of antibiotic as rescue treatment; f) frequency of adverse related events in each
      arm and g) frequency of preeclampsia. Women on active group will receive a combination of at
      least 5*10^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 &amp; Lactobacillus reuteri DSM
      17938, PAC-A and Zinc. Women in control group will receive o Amoxicillin + clavulanic acid
      (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral
      nitrofurantoin (200mg twice per day) ror patients with positive dipstick.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial, double blind allocation concealment, parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomization list will by assembled by independient organization not related with participant, care provider, investigators or sponsors. eCRF will include randomization selection</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and/or Bacteriological cure</measure>
    <time_frame>14 days</time_frame>
    <description>Number of cases with improvement of symptoms severity and/or urinary culture during the first seven days of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of recurrence cases during the rest of pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>6 months</time_frame>
    <description>Time occurred since the finish of treatment until new UTI occurred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of pyelonephritis</measure>
    <time_frame>6 months</time_frame>
    <description>Number of cases of pyelonephritis in each branch</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of preterm babies</measure>
    <time_frame>6 months</time_frame>
    <description>Number of children at delivery with &lt;36wekks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic rescue</measure>
    <time_frame>6 months</time_frame>
    <description>Use of antibiotics for the treatment of pyelonephritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>14 days</time_frame>
    <description>Frequency of adverse events in each branch</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Urinary Tract Infection in Pregnancy</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5*10^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 &amp; Lactobacillus reuteri DSM 17938, PAC-A and Zinc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>The Probiotic group will receive Sachet 1 - contains an instant cranberry drink, consisting of xylitol, monosodium citrate, cranberry aroma, cranberry extract, grape-skin extract, xanthan gum, acesulfame potassium and zinc gluconate and Sachet 2 - contains a total of 5*10^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 &amp; Lactobacillus reuteri DSM 17938, mixed with maltodextrin. Both Sachets should be administered Day 1-14, twice per day This group will also receive for Placebo for Antibiotic treatment day 1-7, twice per day</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics</intervention_name>
    <description>Patient in this group will receive for 7 days Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick. This group will also receive for placebo for probiotics 2 sachets for 14 days</description>
    <arm_group_label>Antibiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women on the second or third trimester of pregnancy with positive urine
             culture according to the operational definition with or without symptoms

          -  Age 18 to 40 years

          -  Verbal and Written Informed Consent for participation in the study

        Exclusion Criteria:

          -  Pathologic pregnancy (different for UTI)

          -  No supplementation of probiotics 2 weeks before study start or during the study
             period.

          -  Antibiotic therapy within last 2 weeks before randomization

          -  Known allergies towards the ingredients of the experimental product

          -  Inability to comprehend the study protocol

          -  Systemic diseases

          -  Multiple pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital General Dr. Manuel Gea Gonzalez</name>
      <address>
        <city>Mexico city</city>
        <state>Tlalpan</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Nicolle LE. Asymptomatic bacteriuria: when to screen and when to treat. Infect Dis Clin North Am. 2003 Jun;17(2):367-94.</citation>
    <PMID>12848475</PMID>
  </results_reference>
  <results_reference>
    <citation>Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011 Oct 1;84(7):771-6. Review.</citation>
    <PMID>22010614</PMID>
  </results_reference>
  <results_reference>
    <citation>Colgan R, Williams M, Johnson JR. Diagnosis and treatment of acute pyelonephritis in women. Am Fam Physician. 2011 Sep 1;84(5):519-26. Review.</citation>
    <PMID>21888302</PMID>
  </results_reference>
  <results_reference>
    <citation>Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011 Mar 1;52(5):e103-20. doi: 10.1093/cid/ciq257. Review.</citation>
    <PMID>21292654</PMID>
  </results_reference>
  <results_reference>
    <citation>Kazemier BM, Koningstein FN, Schneeberger C, Ott A, Bossuyt PM, de Miranda E, Vogelvang TE, Verhoeven CJ, Langenveld J, Woiski M, Oudijk MA, van der Ven JE, Vlegels MT, Kuiper PN, Feiertag N, Pajkrt E, de Groot CJ, Mol BW, Geerlings SE. Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial. Lancet Infect Dis. 2015 Nov;15(11):1324-33. doi: 10.1016/S1473-3099(15)00070-5. Epub 2015 Aug 5.</citation>
    <PMID>26255208</PMID>
  </results_reference>
  <results_reference>
    <citation>Romero R, Oyarzun E, Mazor M, Sirtori M, Hobbins JC, Bracken M. Meta-analysis of the relationship between asymptomatic bacteriuria and preterm delivery/low birth weight. Obstet Gynecol. 1989 Apr;73(4):576-82.</citation>
    <PMID>2927852</PMID>
  </results_reference>
  <results_reference>
    <citation>Ho M, Chang YY, Chang WC, Lin HC, Wang MH, Lin WC, Chiu TH. Oral Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 to reduce Group B Streptococcus colonization in pregnant women: A randomized controlled trial. Taiwan J Obstet Gynecol. 2016 Aug;55(4):515-8. doi: 10.1016/j.tjog.2016.06.003.</citation>
    <PMID>27590374</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2017</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Innovacion y Desarrollo de Estrategias en Salud</investigator_affiliation>
    <investigator_full_name>Pedro Gutierrez Castrellon</investigator_full_name>
    <investigator_title>Head of Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Nitrofurantoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

